Treatment of childhood and adolescent mature B-cell lymphoma
10.3969/j.issn.1000-3606.2014.05.001
- VernacularTitle:儿童和青少年成熟B细胞非霍奇金淋巴瘤临床诊治探讨
- Author:
Yijin GAO
- Publication Type:Journal Article
- Keywords:
non-Hodgkin lymphoma;
B-cell;
children;
adolescent
- From:
Journal of Clinical Pediatrics
2014;(5):401-404
- CountryChina
- Language:Chinese
-
Abstract:
Mature B-cell non-Hodgkin lymphoma (B-NHL) represents about 55%-60%of all NHL cases in children and adolescents. Burkitt lymphoma and diffuse large B-cell lymphoma are the most common subtypes. Current combination chemo-therapy regimen succeeds in overall survival rates of more than 80%. Risk factors for the prognosis of childhood and adolescent B-NHL include bone marrow and central nervous system involvement, serum lactate dehydrogenase level and kinetics of re-sponse to therapy. Future strategies should include further understanding of the genetic alternation of B-NHL and utilization of novel target therapies to decrease treatment-related toxicity. We performed a retrospective analysis on the treatment of child and adolescent mature B-cell lymphoma.
